VIVIMEDLAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VIVIMEDLAB, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
VIVIMEDLAB financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for VIVIMEDLAB, switchable between annual and quarterly views, consolidated or standalone.
VIVIMEDLAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹50.74 Cr and reported EPS of ₹-2.92.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 |
| Other Income | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 |
| Total Income | 1,195 | 1,338 | 1,067 | 871 | 239 | 188 | 159 | 121 |
| Cost of Goods Sold (COGS) | 480 | 518 | 463 | 355 | 153 | 272 | 71 | 60 |
| Gross Profit | 706 | 797 | 596 | 507 | 84 | -84 | 78 | 56 |
| +Operating Expenses | 494 | 620 | 588 | 483 | 92 | 103 | 111 | 69 |
| EBITDA | 212 | 177 | 8 | 24 | -8 | -187 | -33 | -13 |
| +Non-Operating Expenses | 136 | 134 | 126 | 109 | 58 | 144 | 22 | 23 |
| Profit Before Tax (PBT) | 86 | 66 | -109 | -76 | -65 | -331 | -46 | -31 |
| +Tax Expense | 10 | 9 | -0 | 2 | 3 | -2 | -0 | 0 |
| Profit After Tax (PAT) | 76 | 57 | -109 | -78 | -68 | -329 | -45 | -31 |
| Earnings Per Share (EPS) | 9.44 | 13.90 | -13.16 | -9.38 | -8.16 | -39.56 | -5.48 | -3.80 |
| Diluted Shares Outstanding (Nos.) | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| +Additional Disclosures | 1,589 | 1,848 | 1,639 | 1,302 | 457 | 791 | 277 | 212 |
| Sales Growth % | — | 10.92 | -19.49 | -18.64 | -72.46 | -21.15 | -20.33 | -22.00 |
| YoY Sales Growth % | — | 10.92 | -19.49 | -18.64 | -72.46 | -21.15 | -20.33 | -22.00 |
| Material Cost % | 41 | 43 | 46 | 41 | 64 | 59 | 60 | 50 |
| Employee Cost % | 17 | 18 | 22 | 23 | 15 | 17 | 23 | 24 |
| Other Cost % | 25 | 29 | 34 | 33 | 23 | 38 | 52 | 35 |
| OPM % | 18 | 13 | 1 | 3 | -3 | -100 | -22 | -11 |
| Tax % | 11 | 13 | 0 | -3 | -4 | 1 | 1 | -0 |
| Profit Growth % | — | -24.61 | -290.21 | 28.70 | 13.04 | -385.64 | 86.17 | 30.69 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Additional Fields | 156 | 110 | -59 | -32 | -26 | -296 | -53 | -33 |
VIVIMEDLAB segment analysis: revenue and profit mix.
Disclosed business segments at VIVIMEDLAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
VIVIMEDLAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
VIVIMEDLAB investment thesis: bull case, bear case, and the flip lines.
Why someone would buy VIVIMEDLAB, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
What you're getting.
No strengths or opportunities on record.
What can break it.
No weaknesses or threats on record.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 10.17. Balance sheet risk re-prices growth multiples fast.
VIVIMEDLAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VIVIMEDLAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
VIVIMEDLAB technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for VIVIMEDLAB — derived from the live tape, not yesterday's close.
VIVIMEDLAB last traded at ₹7.39 with an intraday range of ₹7.36–₹7.79 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹7.39| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 8.53 | +1.14 | +15.38% |
| R3 | 8.10 | +0.71 | +9.56% |
| R2 | 7.94 | +0.55 | +7.49% |
| R1 | 7.67 | +0.28 | +3.74% |
| PIVOT | 7.51 | 0.12 | 1.67% |
| CURRENT | 7.39 | — | — |
| S1 | 6.38 | -1.01 | -13.71% |
| S2 | 6.81 | -0.58 | -7.89% |
| S3 | 7.08 | -0.31 | -4.15% |
| S4 | 7.24 | -0.15 | -2.07% |
VIVIMEDLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Inside opening range
VIVIMEDLAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VIVIMEDLAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VIVIMEDLAB stood at 74.0% of traded volume, against a 20-day average of 85.0%.
VIVIMEDLAB announcements: results, concalls, ratings, M&A.
Filings VIVIMEDLAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VIVIMEDLAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 45 documents below.
Updates
Vivimed Labs Limited has informed the Exchange regarding 'Board meeting postponed'.
Corporate Insolvency Resolution Process
Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
Corporate Insolvency Resolution Process
Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Updates
Vivimed Labs Limited has informed the Exchange regarding 'Not Large Corporate'.
VIVIMEDLAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VIVIMEDLAB has declared, sequenced by announce and record date.
VIVIMEDLAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About VIVIMEDLAB: business, sector, key facts.
What VIVIMEDLAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VIVIMEDLAB operates in the Pharmaceuticals industry under the Health Care sector.
Questions investors ask about this stock (VIVIMEDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of this stock (VIVIMEDLAB)?
The current share price of this stock (VIVIMEDLAB) is ₹7.39. Today, the stock has declined by ₹0.24 (3.15%), trading in a range of ₹7.36 to ₹7.79. The stock opened at ₹7.63 with a trading volume of 1,46,861 shares.
02Is this stock stock a good investment for long-term?
this stock can be considered for long-term investment based on several factors. The company has a market capitalization of ₹50.74 crores, P/E ratio of 0.00, ROE of -264.84%, and ROCE of 0.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of this stock stock?
The 52-week high price of this stock (VIVIMEDLAB) is ₹29.4, while the 52-week low is ₹5.15. Currently trading at ₹7.39, the stock is 9.2% away from its 52-week low and 74.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy this stock stock at the current price?
Whether to buy this stock stock at ₹7.39 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.35. Today's performance shows a loss of 3.15%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of this stock and when is the next dividend?
this stock offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹7.39, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of this stock?
this stock's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.35, ROE: -264.84%, ROCE: 0.00%, Dividend Yield: 0.00%, EPS: ₹-2.92, Book Value: ₹4.75, and Debt-to-Equity: 9.67. The company's market cap stands at ₹50.74 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is this stock stock performing today in the market?
this stock stock opened at ₹7.63 and is currently trading at ₹7.39, showing a decline of ₹0.24 (3.15%). The intraday high is ₹7.79 and low is ₹7.36. The trading volume stands at 1,46,861 shares, indicating moderate market participation today.
08What is the P/E ratio of this stock and what does it indicate?
this stock has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-2.92, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about the company (VIVIMEDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy